Logo

SNGX

Soligenix, Inc.

SNGX

Soligenix, Inc. • NASDAQ
$1.59 ▲ 8.16% (+0.12)
Market Cap $16.03 M
52w High $6.23
52w Low $1.09
Dividend Yield 0%
P/E -0.46
Volume 394.96K
Outstanding Shares 10.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.58M ▼ $-2.531M ▲ 0% $-0.58 ▲ $-2.53M ▲
Q2-2025 $0 $2.764M ▼ $-2.702M ▲ 0% $-0.82 ▲ $-2.763M ▲
Q1-2025 $0 $3.312M ▼ $-3.237M ▼ 0% $-1.06 ▲ $-3.311M ▲
Q4-2024 $0 $3.712M ▲ $-2.987M ▼ 0% $-1.19 ▼ $-3.711M ▼
Q3-2024 $0 $1.865M $-1.719M 0% $-0.78 $-1.864M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.525M ▲ $11.294M ▲ $3.696M ▼ $7.598M ▲
Q2-2025 $5.098M ▼ $5.761M ▼ $3.932M ▼ $1.829M ▼
Q1-2025 $7.297M ▼ $7.746M ▼ $4.134M ▼ $3.612M ▼
Q4-2024 $7.82M ▼ $8.966M ▼ $4.848M ▲ $4.118M ▼
Q3-2024 $9.84M $10.477M $4.542M $5.935M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.416M ▲ $-2.742M ▼ $-3.313K ▼ $545.635K ▼ $-2.2M ▼ $-2.745M ▼
Q1-2025 $-3.237M ▼ $-1.847M ▲ $0 $1.325M ▲ $-522.343K ▲ $-1.847M ▲
Q4-2024 $-2.987M ▼ $-2.233M ▲ $0 $242.878K ▼ $-2.021M ▼ $-2.233M ▲
Q3-2024 $-1.719M ▼ $-2.91M ▼ $0 $3.293M ▼ $427.638K ▼ $-2.91M ▼
Q2-2024 $-1.645M $-1.918M $0 $4.235M $2.321M $-1.918M

Revenue by Products

Product Q1-2024Q2-2024Q3-2024Q4-2024
Grant revenue
Grant revenue
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Soligenix has essentially no product revenue yet and has been running at steady, modest operating losses for several years. This is typical for a small, late‑stage biotech that is still developing its pipeline. The repeated losses show that the business is still firmly in the investment phase, with spending focused on research, development, and overhead rather than on commercial activities. The very large swings in reported earnings per share mainly reflect the impact of repeated reverse stock splits rather than big changes in the underlying dollar losses.

Balance Sheet

Balance Sheet The balance sheet is very small and almost entirely made up of cash, with little or no traditional debt. That limits financial leverage risk but also highlights how constrained the company’s resources are. Equity is thin, which is common for micro‑cap biotechs that have funded themselves through repeated equity raises over many years. Overall, the company appears financially lightweight: it does not carry heavy obligations, but it also does not have a deep capital cushion to absorb prolonged setbacks.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing development spending without offsetting revenue. Free cash flow is also negative, but there is virtually no spending on physical assets, which is typical for a drug developer whose main costs are people and clinical trials rather than factories. In practical terms, the company is burning cash at a steady pace and remains dependent on external funding sources such as equity offerings, grants, and potential partnership payments to sustain its programs.

Competitive Edge

Competitive Edge Competitively, Soligenix is trying to build strength in narrow, underserved niches: rare skin lymphomas, oral mucositis, and biodefense vaccines. In these areas, there are fewer direct rivals and meaningful unmet medical needs, which can support better pricing and regulatory advantages if products are approved. The company’s patents, orphan‑drug and fast‑track designations, and specialized platforms (like its visible‑light photodynamic therapy and thermostable vaccines) provide some protection against copycats. However, the firm remains small compared to larger biotech and pharma players, which can outspend it in trials, marketing, and partnering, and there is still competition from existing off‑label treatments and alternative technologies.

Innovation and R&D

Innovation and R&D Innovation is the core of Soligenix’s story. It is advancing several distinct platforms: a topical light‑activated therapy for cutaneous T‑cell lymphoma, an innate immune modulator for inflammation and tissue healing, and a vaccine‑stabilization technology that could simplify storage and stockpiling of complex vaccines. These platforms have attracted regulatory incentives and government interest, especially on the biodefense side. At the same time, most assets are still in the development or registration pathway, and prior trials have delivered mixed results in some indications. Future value depends heavily on successful late‑stage studies, regulatory approvals, and the company’s ability to form partnerships that can help fund and commercialize these innovations.

Summary

Soligenix is a tiny, pre‑revenue biotech with a highly specialized pipeline and a long history of reverse splits and capital raises. Financially, it operates with minimal assets and no meaningful revenue, relying on steady but ongoing cash burn to push late‑stage programs forward. Strategically, its focus on orphan diseases and biodefense, backed by proprietary technologies and regulatory designations, offers clear potential if key drug and vaccine candidates clear clinical and regulatory hurdles. The trade‑off is high execution risk: progress hinges on positive trial outcomes, regulatory decisions, continued access to external funding, and the ability to translate promising science into a sustainable commercial business.

NEWS

November 19, 2025 · 7:30 AM UTC

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Read more

November 7, 2025 · 7:30 AM UTC

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Read more

October 14, 2025 · 7:30 AM UTC

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Read more

October 7, 2025 · 7:30 AM UTC

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Read more

September 30, 2025 · 7:30 AM UTC

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Read more